1. トップ >
  2. Medical Affairs Website >
  3. 糖尿病領域Publication一覧

糖尿病領域Publication一覧

最終更新：2025/4

こちらには弊社社員が著者に含まれる論文や、弊社から資金提供・原薬提供などを行った研究論文を掲載しています。

糖尿病領域

疾患領域ページ（会員限定）では、こちらに掲載している論文以外の論文も掲載していますので、是非ご覧ください。

糖尿病領域（会員限定）ページはこちら

2025開く

    ＜英文＞

  • Imeglimin, unlike metformin, does not perturb differentiation of human induced pluripotent stem cells towards pancreatic β-like cells and rather enhances gain in β cell identity gene sets

    T.Imada et al. J Diabetes Investig. 2025 Jan 20. doi: 10.1111/jdi.14410. Online ahead of print.

  • Differential effects of imeglimin and metformin on insulin and incretin secretion-An exploratory randomized controlled trial

    R.Usui et al. Diabetes Obes Metab. 2025 Feb;27(2):856-865

2024開く

    ＜英文＞

  • Gastrointestinal symptoms in patients receiving imeglimin in combination with metformin: A post-hoc analysis of imeglimin clinical trial data

    J.Ito et al. J Diabetes Investig. 2024 Dec 26. doi: 10.1111/jdi.14396. Online ahead of print.

  • Imeglimin Halts Liver Damage by Improving Mitochondrial Dysfunction in a Nondiabetic Male Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis

    K.Kaji et al. Antioxidants. 2024 Nov 18;13(11):1415.

  • Rationale and Design of the Study to Investigate the Metabolic Action of Imeglimin on Patients with Type 2 Diabetes Mellitus (SISIMAI).

    T.Tajima et al. Diabetes Ther. 2024 Sep 30;15: 2569-2580.

  • Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data-driven cluster analysis: A post-hoc analysis of imeglimin clinical trial data.

    K.Hagi et al. Diabetes Obes Metab. 2024 Sep;26(9):3732-3742.

  • Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high-fat, high-sucrose diet-fed mice.

    O.Kikuchi et al. J Diabetes Investig. 2024 Sep;15(9):1177-1190.

  • Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus.

    K.Hagi et al. J Diabetes Investig. 2024 May 25; 15(9): 1239-1247

  • Imeglimin mitigates　the accumulation of dysfunctional　mitochondria to restore insulin　secretion and suppress apoptosis　of pancreatic β‑cells from db/db　mice.

    K.Aoyagi et al. Sci Rep.2024 Mar 14;14(1)_6178

  • Imeglimin Exhibits Novel Anti-Inflammatory Effects on High-Glucose-Stimulated Mouse Microglia through ULK1-Mediated Suppression of the TXNIP–NLRP3 Axis.

    H.Kato et al. Cells. 2024 Feb 5;13(3):284

  • Imeglimin improves systemic metabolism by targeting brown adipose tissue and gut microbiota in obese model mice.

    M.Awazawa et al. Metabolism. 2024 Apr:153:155796.

2023開く

    ＜英文＞

  • Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.

    K.Hagi et al. J Diabetes Investig. 2023 Nov;14(11):1246-1261.

  • Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials.

    K.Hagi et al. J Diabetes Investig. 2023 Sep;14(9):1101-1109.

  • Prescription patterns and therapeutic effects of second-line drugs in Japanese patients with type 2 diabetes mellitus: Analysis of claims data for metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycemic agents.

    R.Nishimura et al. Expert Opin Pharmacother. 2023 Jun;24(8):969-976.

  • Pharmacokinetics and Safety of Imegliminin Japanese Patients With Impaired RenalFunction.

    A.Kitamura et al. The Journal of Clinical Pharmacology. 2023

  • Stimulatory effect of imeglimin on incretin secretion.

    Q.Yingyue et al. J Diabetes Investig. 2023 Jun;14(6):746-755.

  • Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes.

    K.Hozumi et al. Sci Rep. 2023 Jan 13;13(1):746.

  • Prevalence and predictors of clinical inertia in patients with type 2 diabetes who were treated with a single oral antidiabetic drug.

    R.Suzuki et al. J Diabetes Investig. 2023 Jan;14(1):81-91.

    • ＜和文＞

  • 膵作用と膵外作用の2 つの血糖降下作用をあわせもつ世界初の経口2 型糖尿病治療薬イメグリミン塩酸塩（ツイミーグ®錠）の薬理学的特性と臨床効果．

    長嶺純, 日薬理誌(Folia Pharmacol. Jpn.) ,2023, 158，P.1～10

2022開く

    ＜英文＞

  • Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis.

    R.Nishimura et al. Adv Ther. 2022 Jan; 39(1):632-654.

  • Comparison of the effects on cardiovascular events between use of metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycaemic agents in Japanese patients with type 2 diabetes mellitus: a claims database analysis.

    R.Nishimura et al. BMJ Open. 2022 Mar;12(3):e045966.

  • Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.

    C.Reihac et al. Diabetes Obes Metab. 2022 May;24(5):838-848.

  • Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules.

    J.Sanada et al. Scientific Reports. 2022 Aug 2;12(1):13220.

  • Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using 111In-exendin-4 SPECT/CT imaging and the perspective of mitochondrial involvements.

    M.Fauzi et al. Front Endocrinol (Lausanne). 2022 Sep 29;13:1010825.

  • Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes.

    Y.Tomita et al. Clin Transl Sci. 2022 Apr;15(4):1014-1026.

2021開く

    ＜英文＞

  • Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes.

    Y.Nagai et al. Diabetes Ther. 2021; 12:897–911.

  • A Claims Database Analysis of Dose-Dependency of Metformin and Incidence of Lactic Acidosis in Japanese Patients with Type 2 Diabetes.

    Y.Nagai et al. Diabetes Ther. 2021; 12:1129–1141.

  • Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study.

    M.Odawara et al. Diabetes Ther. 2021 Aug;12(8):2165-2177.

  • Imeglimin prevents heart failure with preserved ejection fraction by recovering the impaired unfolded protein response in mice subjected to cardiometabolic stress.

    H.Kitakata et al. Biochem Biophys Res Commun. 2021 Oct 1;572:185-190.

  • Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.

    J.Dubourg et al. Diabetes Care. 2021 Apr;44(4):952-959.